HIGHLIGHTS
SUMMARY
Current guidelines suggest the use of insulin as basal bolus or continuous subcutaneous insulin infusion (CSII) in Type 1 diabetes_mellitus (T1DM) and for hospitalized patients. Treatment for Type 2 diabetes_mellitus (T2DM) consists of antidiabetic agents and insulin as basal, basal plus, or basal bolus administration. The exclusion criteria consisted of observational studies, case reports, case series, Phase I/II pharmacokinetic, and dose-determination studies, in_vitro studies, animal studies, studies on a pediatric population, studies with only T1DM patients, studies with no full text available, or studies where the full text did not provide adequate . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.